A Phase II trial of ZLX-1 for treating stress-related insomnia.
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2017
At a glance
- Drugs ZLX 1 (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 25 Aug 2017 According to a Blake Insomnia Therapeutics media release, the company has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
- 25 Feb 2017 According to a Blake Insomnia Therapeutics media release, company is planning to submit a New Drug Application in Canada with US in Q2 2017 and International submissions to follow later.
- 08 Feb 2017 According to Blake Insomnia Therapeutics media release, this trial is planned for Q2 2017, with successful filing and approval, the product is expected to be launched in the US in 2022.